Polymyositis (PM) is a disorder of unknown aetiology characterised by an inflammatory myopathy involving striated skeletal and less commonly cardiac muscles. A diagnosis of dermatomyositis (DM) is made when characteristic skin lesions accompany the myositis. Available reports on PM/DM is based mainly on studies conducted in white populations. As Singapore has a very different demographic profile, this study was carried out to determine possible similarities and differences in clinical and laboratory features and treatment response of our patients with PM/DM.
Abstract
Objectives-To determine possible similarities and differences in clinical and laboratory features and treatment response between patients in Singapore with polymyositis (PM) and dermatomyositis (DM) and reported series. Methods-Case records of adult patients (16 years We believe we have covered more than 95% of PM/DM cases diagnosed during the five year study period.
Data collection and analysis The case records of the patients were reviewed in January 1992. Data entry was performed using DBase III plus and analysed using the SAS statistical package. Data were evaluated by demographic features, clinical features at presentation, site and type of malignancy, associated connective tissue disorders, serological parameters, muscle enzymes, EMG and muscle biopsy, cardio-pulmonary involvement and response to therapy. Population denominators were based on 1990 census data for the relevant age groups.
Results
Eighty five patients had a diagnosis of PM/DM but ten were excluded from the study (9 were first diagnosed outside the study period and 1 was below 16 years old). The 75 patients had a total duration of follow up of 1035 months (range: 1 to 57 months). The median duration of follow up was 8 months. A total of 49.3% (n = 37) of the study population were still on follow up at the time of the chart review, 26-7% (n = 20) had died and 24% (n = 18) were lost to follow up.
Thirty five patients had polymyositis and 40 had dermatomyositis. (M:F=1:3.35) than DM (M:F=1:1.22). This difference was statistically significant (p < 0 05).
The ethnic distribution of the study population closely followed that of the general population. There were 66 (88%) Chinese, 5 (6-7%) Malays, 2 (2-7%) Indians and 2 (2.7%) of other ethnic origin (table 1) . There was no significant difference in the ethnic distribution of PM and DM.
The mean and median age at diagnosis was 50 3 years and 50 7 years respectively (SD 16-7 years, range 19-2 to 83 1 years). The average age at diagnosis was 49 and 52-3 years for PM and DM respectively and this difference was not statistically significant. The mean age at diagnosis was higher for the subgroup with malignancy (61-8 years) and this was statistically significant (p < 0-001) (table 1) . Patients in the connective tissue disease overlap group were youngest with a mean age of 38-3 years.
Clinicalfeatures at presentation At presentation, 86-7% (n = 65) had proximal myopathy, 32% (n = 24) had neck muscle weakness and only 10.7% (n = 8) had dysphagia (table 2) . Dysphagia was more common in subgroups II and IV at diagnosis but this was not statistically significant. Cutaneous vasculitis was present in 18-7% (n = 14) of patients. Of the four patients with malignancy detected at the time of presentation of PM/DM, three had cutaneous vasculitis. Arthritis/arthralgia was present in 34.7% (n = 26) of patients and most commonly found in subgroup IV patients. Raynaud's phenomenon was present in only 5 (6-7%) patients. A total of 14-7% of patients (n = 11) had interstitial lung disease and 17-3% (n = 13) had abnormal ECG. Significant differences were found at presentation amongst the four subgroups with respect to proximal myopathy, rash, cutaneous vasculitis and arthritis (p < 0 05) ( (table 7) . Of the 10 patients whose relapses were known, 7 had one relapse and 2 had two relapses.
The mean age at diagnosis of patients who remitted was 46-4 years, 10-1 years younger than the non-remitting group (p < 0 05). The duration of symptoms before diagnosis, the presence of malignancy, associated autoimmune diseases, dysphagia, cardiac or pulmonary involvement and ANA positivity (without associated connective tissue disorders) did not influence remission.
Mortality
As at June 1991, 14 DM and 6 PM patients had died (table 8) . The main causes of death were infection (9 patients) and malignancy (5 patients). Only 2 of the patients died of PM/ DM related causes (one had respiratory muscle weakness and the other had respiratory failure from interstitial lung disease). The mean and median interval between diagnosis and death was 4-6 and 2-4 months respectively (range 0 5 to 14-4 months). There was no significant difference in survival rates between PM and DM patients. On multivariate analysis using a stepwise procedure and log rank test, nonremission and presence of dysphagia were found to be significantly associated with poorer survival. This conclusion should be interpreted with caution as the median follow up of our study population was only 8 months.
Discussion
The incidence, clinical and laboratory features and treatment response of 75 adult-onset PM! DM patients were analysed retrospectively. In the interpretation of the findings from this study, it should be noted that Singapore is a small island state and almost all PM/DM cases are investigated and managed in a tertiary setting. We reviewed reported studies on PM/ DM and were not always able to compare our findings with earlier published reports because of differences in classification criteria and in subgroupings. Many studies also included childhood PM/DM. The reported annual incidence of PM/DM varied from 2-18 to 10 cases per million population per year.2`4 Our annual incidence of 7-7 cases per million population is similar to that reported in the USA where there is an estimated 5 to 10 new cases per million population per year.3 5 As in previous studies, PM/DM occurs more commonly in females.3 69 The mean age at diagnosis of our 4 subgroups is similar to the UCLA'0 and Australian7 series. Our patients with malignancy have the oldest mean age and those in the overlap subgroup are the youngest. Other studies have also shown that malignancy is more frequent in older patients.9-
The presenting clinical features of our patients are similar to reported series, the most common being symmetrical proximal muscle weakness, rash and arthralgia/arthritis. Our study population as in the UCLA series'0 and the New Zealand series'2 have a low prevalence of dysphagia (10-7%) compared with most reports with frequencies of dysphagia between 24% and 45%3.2 Although Hochberg et al6 found dysphagia to be most common in patients with malignancy, this was not supported by us as well as others.8 " The prevalence of Raynaud's phenomenon in previous reports varied from 17% to 550/o,6 7 9 10 found mainly in the overlap group. Our patients have an extremely low frequency of this clinical feature. Our study concurred with others in that abnormal ECG findings namely ST-T wave abnormalities are most frequent followed by arrhythmia and heart block.2 6 10 The majority of the patients did not have angiographic or echocardiographic evaluations and it was therefore difficult to ascertain if these changes were related to cardiac involvement by the inflammatory disease. The ECG abnormalities in the malignancy subgroup where patients were significantly older were not as frequent as subgroups I and II, thus suggesting that these abnormalities were related to the underlying inflammatory disease.
Muscle enzymes, EMG and muscle biopsy positivity in our study is comparable to reported series.2 6 7 ESR appears to be a useful index of disease activity for our patients as almost half have ESR above 50 mm/hour at diagnosis. This contrasts with other reports where only about 20% have this degree of elevation of ESR. 7 9 The reported prevalence of ANA varied from 15% to 59%2 6 7 10 13 and in our group it was 47 3%. As expected, the frequency of ANA, RF, anti-RNP, anti-Sm and anti-Ro antibody was the highest in the subgroup with overlap disease. The previous report of anti-Ro antibody being a marker for cardiac injury in myositis' was not substantiated by our study.
None of the patients with positive anti-Ro antibody had cardiac abnormality. Although our study population revealed a similar proportion of patients with overlap disease as in reported series,6 10 the frequency of the type of connective tissue disease differs.
Sjogren's syndrofme and systemic sclerosis were uncommon in our patients. SLE was the most common and this probably reflects the frequency of these connective tissue diseases in our population. (Unfortunately data on the prevalence or incidence of these inflammatory rheumatic disorders in Singapore is not available).
Reports on the prevalence of malignancy in PM/DM varied from 7% to 28%. Corticosteroids are considered the treatment of choice for PMIDM although prospective randomised trials have never been carried out.4 9 24 In our study, during the initial episode of myositis, only 14-7% (n = 11) received single immunosuppressive agents in combination with corticosteroid as a result of poor response or adverse effects of the latter. However, only 56-5% (35/62) of those on prednisolone alone remitted suggesting that possibly more should recieve immunosuppressive agents. As this is a retrospective study and the patients were under the care of their personal rheumatologist, neurologist, dermatologist and in a few instances physicians, this data on therapy reflected the preferences of the doctors.
The factors identified for poor response to treatment in previous studies include acute fulminant disease,4 presence of connective tissue disease4 9 and malignancy4 9 as well as long disease duration.5 Tymms' series7 showed that the patient's sex and presence of associated connective tissue disease did not influence response to treatment. In our study, the only poor prognostic factor identified with regards to remission was age. The mean age at diagnosis of patients who achieved remission was significantly younger than those who did not remit after controlling for malignancy, associated autoimmune disease, dysphagia, cardiac, pulmonary disease at presentation or ANA positivity in the absence of associated connective tissue disorder. The duration of symptoms before diagnosis was also not related to remission status.
Acute onset of disease,2 failure to induce remission,2 non-whites,25 26 elderly,2 6 10 25 26 presence of dysphagia,21 26 normal CK levels,27 cutaneous vasculitis,22 malignancy8 9 22 as well as pulmonary fibrosis28 were some of the factors cited for poorer survival. In our study we found non-remission and dysphagia to be significantly associated with poorer survival. As the median duration of follow up was only 8 months, we cannot confidently propose these to be important factors affecting survival. A long term prospective study of PM/DM patients relating their clinical features to course of disease, response to therapy and survival would be useful.
In conclusion, the results of our study suggest ethnicity does not influence the expression of PMIDM in view of the considerable similarities in frequency and clinical expression of disease in our population compared with series from other countries.
